Enhancing Calm in Arab Elderly With Dementia (sn/dm)

Mostafa Shaban

Status

Invitation-only

Conditions

Agitation in Dementia, Including Alzheimer's Disease

Dementia

Treatments

Behavioral: Integrated Snoezelen-Aromatherapy-Personal Item Therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT06216275

Snoezelen_Demntia

Details and patient eligibility

About

The goal of this clinical trial is to evaluate the effectiveness of integrating Snoezelen methods with aromatherapy and personal items in reducing agitation in Arab elderly individuals with dementia. The main questions it aims to answer are:

Does the combination of Snoezelen methods, aromatherapy, and the use of personal items significantly reduce agitation in elderly Arab patients with dementia compared to standard care practices? How do patients and caregivers perceive the impact of this integrated approach on the overall well-being and quality of life of the patients?

Participants in this study will:

Engage in sessions utilizing Snoezelen methods, a multi-sensory environment designed to deliver stimuli to various senses.

Receive aromatherapy treatments with selected scents known for their calming properties.

Be provided with personal items that are familiar and meaningful to them, to create a sense of comfort and security.

Full description

This clinical trial is centered on a novel approach to dementia care, specifically targeting the Arab elderly demographic. It uniquely combines three elements - Snoezelen therapy, aromatherapy, and the use of personal items - to address agitation, a common and challenging symptom in dementia patients.

Snoezelen Therapy Implementation:

Custom-designed Snoezelen rooms will be used, equipped with lights, colors, sounds, and textures to stimulate senses in a controlled manner.

Sessions will be tailored to individual patient needs and preferences, monitored by trained staff.

Aromatherapy Application:

Selection of aromas will be based on their known calming properties, with a focus on cultural relevance and acceptability in the Arab elderly population.

The method of delivery and duration of each aromatherapy session will be standardized to ensure consistency across the study.

Incorporation of Personal Items:

Patients will be encouraged to select personal items that hold significant emotional value or are tied to pleasant memories.

These items will be integrated into the therapy sessions to provide a sense of familiarity and emotional comfort.

Data Collection and Analysis:

Quantitative data on agitation levels will be gathered using established agitation scales, both pre- and post-intervention.

The study aims to provide a comprehensive evaluation of how this integrated approach can influence agitation in dementia, considering both statistical effectiveness and personal experiences. The outcome will contribute valuable insights into dementia care practices, particularly for the Arab elderly population, and may offer a template for culturally sensitive dementia care.

Enrollment

80 estimated patients

Sex

All

Ages

60 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

For the study "Enhancing Calm in Arab Elderly with Dementia: Integrating Snoezelen Methods with Aromatherapy and Personal Items to Reduce Agitation", here are the suggested Inclusion and Exclusion Criteria:

Inclusion Criteria:

Age: Participants must be 65 years to 90 years
Diagnosis: Clinical diagnosis of dementia required.
Ethnicity: Must be of Arab descent.
Agitation Levels: Must show agitation signs based on a standardized scale.
Cognitive Function: Adequate cognitive function for study participation, verified by standard assessment.

Exclusion Criteria:

Severe Medical Conditions: Individuals with severe medical conditions that could affect study participation or health.
Advanced Dementia: Patients with very advanced dementia stages, unable to engage in study activities.
Allergies: Known allergies to aromatherapy products used in the study.
Recent Medication Changes: Significant changes in dementia medication regimen before the study.